News & Updates
Filter by Specialty:

Long-term glucocorticoid exposure ups risk of incident CVD
Long-term glucocorticoid levels, particularly cortisone measured in scalp hair, are associated with a higher risk of incident cardiovascular disease (CVD) among younger adults, suggests a study.
Long-term glucocorticoid exposure ups risk of incident CVD
15 Oct 2024
Music a perioperative aide for lung cancer patients?
Individuals with resectable stage IA to IIIB non-small cell lung cancer (NSCLC) who plan to receive minimally invasive lung surgery may benefit from intensity-based personalized music therapy (IBP-MT) suggests the phase II Music of Lung Health II study.
Music a perioperative aide for lung cancer patients?
15 Oct 2024
Phototherapy for psoriasis at home as good as in the office
Narrowband ultraviolet B (NB-UVB) phototherapy or light therapy performed at home is as good as one done in the doctor’s office in patients with plaque and guttate psoriasis, as shown in the randomized Light Treatment Effectiveness (LITE) trial presented at EADV 2024.
Phototherapy for psoriasis at home as good as in the office
15 Oct 2024
Psoriasis patients with overweight, obesity may need higher vunakizumab dosage
In the treatment of moderate-to-severe psoriasis, patients with overweight or obesity appear to have a diminished response to vunakizumab compared with those who have lower BMIs, according to a post hoc subgroup analysis of a phase III trial.
Psoriasis patients with overweight, obesity may need higher vunakizumab dosage
14 Oct 2024
Endoscopic ARMS improves symptoms, QOL in GERD
Patients with gastroesophageal reflux disease (GERD) who underwent endoscopic antireflux mucosectomy (ARMS) see improvements in their symptoms, a reduction of medical therapy, and a better quality of life (QOL), reports a study.
Endoscopic ARMS improves symptoms, QOL in GERD
14 Oct 2024
Ebdarokimab works wonders for patients with plaque psoriasis
A recent study has shown the safety and efficacy of AK 101 (ebdarokimab) in the treatment of patients with plaque psoriasis, achieving ≥75-percent improvement in Psoriasis Area and Severity Index (PASI 75) and Static Physicians Global Assessment (sPGA) 0/1 response.
Ebdarokimab works wonders for patients with plaque psoriasis
14 Oct 2024
MARIPOSA update: Amivantamab-lazertinib bests osimertinib for EGFRm NSCLC at 3 years
The updated efficacy analysis of the phase III MARIPOSA trial continues to favour amivantamab plus lazertinib over osimertinib for first-line (1L) treatment of patients with EGFR-mutant (EGFRm) advanced non-small cell lung cancer (NSCLC).